Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759317 · ClinicalTrials.gov registry record · Phase 4
Physiologic Monitoring of Antidepressant Treatment Response
A Phase 4 study of Depression, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT00759317: Completed Phase 4 study of Depression, sponsored by University of California, Los Angeles.
NCT00759317 is a Phase 4 study of Depression that has completed, run by University of California, Los Angeles. The registered enrollment target is 37 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00759317, a Phase 4 study of Depression, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
Study Objectives: * to identify neurophysiologic effects of venlafaxine treatment in normal controls using quantitative EEG (QEEG) cordance * to examine the effects of venlafaxine on different rating scales measuring mood and anxiety (e.g., Ham-D, BDI, SCL-90, POMS-BI, Visual Analog Mood Scale, SSRS, SASS, Q-LES-Q and SF-36) as well as on measures of cognitive and psychosocial function (i.e., Stroop, PASAT, RAVLT, Trailmaking A and B, Digit-Symbol, Grooved Pegboard, Multidimensional Health Locus of Control, Temperament and Character Inventory, Interpersonal Support Evaluation List, Godin Leisure-Time Questionnaire, and Pittsburgh Sleep Quality Index) in normal control subjects, and the association of changes in cordance with changes in thinking and memory. * to identify physiologic effects of venlafaxine treatment in normal controls using heart rate and immune function measures
Conditions Studied
Interventions
- DRUG venlafaxine (Effexor)
Study Locations (1)
California
- UCLA Laboratory of Brain, Behavior, and Pharmacology - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2001-06 |
| Est. Completion | 2002-09 |
| Phase | Phase 4 |
What the finished NCT00759317 record still lists
NCT00759317 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which venlafaxine (Effexor) is the first listed.
NCT00759317 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00759317 about?
NCT00759317 is a clinical study titled "Physiologic Monitoring of Antidepressant Treatment Response". Study Objectives: * to identify neurophysiologic effects of venlafaxine treatment in normal controls using quantitative EEG (QEEG) cordance * to examine the effects of venlafaxine on different rating scales measuring mood and anxiety (e.g., Ham-D, BDI, SCL-90, POMS-BI, Visual Analog Mood Scale, SSR...
What is the current status of trial NCT00759317?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2001-06. Estimated completion is 2002-09.
What conditions does trial NCT00759317 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00759317?
The interventions under investigation include: venlafaxine (Effexor) (DRUG).
Who is sponsoring clinical trial NCT00759317?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00759317 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00759317's enrollment target sits among peer trials
37 535th of 679 higher than 143 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia